Expression of IGF-I and viral proteins (C, NS3, NS5A) in the livers of patients with chronic HCV infection

Advances in Clinical and Experimental Medicine

Volumn 20, Issue 3, 2011, Pages 263-273

  Kasprzak, Aldona ^a   Adamek, Agnieszka ^a   Przybyszewska, Wiesława ^a   Szaflarski, Witold ^a   Sterzyńska, Karolina ^a   Seraszek, Agnieszka ^a   Mozer Lisewska, Iwona ^a   Kaczmarek, Elzbieta ^a   Biczysko, Wiesława ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Chronic infection with HCV; Immunocytochemistry; Insulin like growth factor I; Spatial visualization technique

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; LIVER PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN C; SOMATOMEDIN B; SOMATOMEDIN C;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STEATOSIS; TISSUE MICROARRAY;

HEPATITIS C VIRUS;

EID: 84860400477     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fattovich G, Stroffolini T, Zagni I, Donate F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004, 127, S35-S50
2. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev 2005, 5, 215-229.
3. Colombo M: Hepatitis C virus and hepatocellular carcinoma. Sem Liv Dis 1999, 19, 263-269.
4. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocellular cells against drug-induced apoptosis. Biochem Pharmacol 2004, 86, 1003-1015. (Pubitemid 39094263)
5. Kasprzak A, Adamek A: Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008, 38, 1-26. (Pubitemid 350182573)
6. Lee S, Park U, Lee YI: Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. Virology 2001, 283, 167-177. (Pubitemid 32881164)
7. Le Roith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-growth factor I receptor. Endocr Rev 1995, 16, 143-163.
8. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001, 22, 53-74.
9. Scharf JG, Dombrowski F, Ramadori G: The IGF axis and hepatocarcinogenesis. Mol Pathol 2001, 54, 138-144. (Pubitemid 32539603)
10. Daughday WH, Rotweien P: Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989, 10, 68-91.
11. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988, 81, 976-981.
12. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C: Serum insulin-growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002, 95, 2539-2545. (Pubitemid 35424040)
13. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A: Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 2003, 50, 814-816. (Pubitemid 36613411)
14. Lorenzo-Zuniga V, Bartoli R, Masnou H, Montoliu S, Morillas RM, Planas R: Serum concentration of insulin-like growth factor-I (IGF-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007, 52, 3245-3250. (Pubitemid 47512509)
15. Huynh H, Chow PKH, Ooi LLP, Soo KC: A possible role of insulin-like growth factor-binding protein-3 autocrine/ paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002, 13, 115-122. (Pubitemid 34507101)
16. Okan A, Comlekci A, Akpinar H, Okan I, Yesil S, Tankurt E, Simsek I: Serum concentration of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol 2000, 35, 1212-1215.
17. Mahdy KA, Ahmed HH, Mannaa F, Abdel-Shaheed A: Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J Gastroenterol 2007, 13, 785-790.
18. Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B, Berg T: Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol 2007, 102, 2724-2731. (Pubitemid 350179318)
19. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991, 13, 372-374.
20. Kasprzak A, Adamek A, Biczysko W, Seidel J, Przybyszewska W, Olejniczak K, Juszczyk J, Zabel M: Intracellular expression of the proliferative marker Ki-67 and viral proteins (NS3, NS5A and C) in chronic, long lasting hepatitis C virus (HCV) infection. Folia Histochem Cytobiol 2007, 45, 357-366. (Pubitemid 351193610)
21. Hsu S, Raine L, Fanger H: Use of a avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981, 29, 577-580.
22. st ed., 289-295.
23. Volkmann M, Schiff JH, Hajjar Y, Otto G, Stilgenbauer F, Fiehn W, Galle PR, Hofmann WJ: Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med. 2001, 79, 594-600. (Pubitemid 32938388)
24. Grimberg A: Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003, 2, 630-635.
25. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004, 11, 383-393. (Pubitemid 39336219)
26. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL: p53-dependent transcriptional repression of p21 (waf1) by hepatitis C virus NS3. J Gen Virol 2001, 82, 2235-2241. (Pubitemid 32827604)
27. Stefano JT, Correa-Giannella ML, Ribeiro CMF, Alves VAF, Massarollo PCB, Machado MCC, Giannella-Neto D: Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 2006, 28, 3821-3828. (Pubitemid 44028392)
28. Nikolić JA, Todorović V, Bozić M, Tosić L, Bulajić M, Alempijević T, Nedić O, Masnikosa R: Serum insulin-like growth factor (IGF)-II is more closely associated with liver dysfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta 2000, 294, 169-177. (Pubitemid 30155816)
29. Völzke H, Nauck M, Rettig R, Dörr M, Higham C, Brabant G, Wallaschofski H: Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 2009, 161, 705-713.
30. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000, 87, 118-121. (Pubitemid 30368424)